ADARx Director Reports Two 178,528-Share Option Awards

Each award's remaining shares vest quarterly over three years, subject to continued service on each vesting date.

Rhea-AI Filing Summary

ADARx Pharmaceuticals, Inc. director Mary Tagliaferri reported two directly held stock-option awards, each covering 178,528 common shares. The award granted November 22, 2025 has a $6.25 exercise price and expires November 21, 2035; the award granted July 20, 2026 has an $8.69 exercise price and expires July 19, 2036. Each award vests one-quarter on its first vesting date—November 22, 2026, or July 20, 2027—with the remainder in equal quarterly installments over three years, subject to continued service on each vesting date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider TAGLIAFERRI MARY

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy) F1	--	--	--
holding	Stock Option (right to buy) F2	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 357,056 contracts (Direct)

Footnotes (2)

1. F1. Granted to the Reporting Person on November 22, 2025. 1/4 of the total number of shares vest and become exercisable on November 22, 2026 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
2. F2. Granted to the Reporting Person on July 20, 2026. 1/4 of the total number of shares vest and become exercisable on July 20, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Key Figures

Underlying shares in option award: 178,528 common shares Exercise price: $6.25 per share Underlying shares in option award: 178,528 common shares +1 more

4 metrics

Underlying shares in option award 178,528 common shares Award granted November 22, 2025

Exercise price $6.25 per share Award granted November 22, 2025

Underlying shares in option award 178,528 common shares Award granted July 20, 2026

Exercise price $8.69 per share Award granted July 20, 2026

Key Terms

Stock Option (right to buy), vest and become exercisable, equal quarterly installments, continued service

4 terms

Stock Option (right to buy) financial

"Stock Option (right to buy)"

vest and become exercisable financial

"shares vest and become exercisable"

equal quarterly installments financial

"remaining shares vest and become exercisable in equal quarterly installments thereafter"

continued service financial

"subject to the Reporting Person's continued service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did ADRX director Mary Tagliaferri report?

Mary Tagliaferri reported two directly held stock-option awards, each covering 178,528 common shares. The award granted November 22, 2025 has a $6.25 exercise price; the award granted July 20, 2026 has an $8.69 exercise price.

When do ADRX director Mary Tagliaferri's stock options vest?

The November 22, 2025 award has one-quarter vesting November 22, 2026, with the remaining shares vesting in equal quarterly installments over three years. For the July 20, 2026 award, one-quarter vests July 20, 2027, with the remainder vesting quarterly over three years. Both schedules are subject to continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/26/2026 - 08:35 PM Accepted by SEC EDGAR 09/24/2026 - 06:40 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

TAGLIAFERRI MARY

(Last) (First) (Middle)

C/O ADARX PHARMACEUTICALS, INC.

5871 OBERLIN DRIVE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/24/2026

3. Issuer Name and Ticker or Trading Symbol
ADARx Pharmaceuticals, Inc. [ ADRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	11/21/2035	Common Stock	178,528	$6.25	D
Stock Option (right to buy)	(2)	07/19/2036	Common Stock	178,528	$8.69	D

Explanation of Responses:

1. Granted to the Reporting Person on November 22, 2025. 1/4 of the total number of shares vest and become exercisable on November 22, 2026 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.

2. Granted to the Reporting Person on July 20, 2026. 1/4 of the total number of shares vest and become exercisable on July 20, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jiang Bian , Attorney-in-Fact	09/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)